Improved hemostasis with the combination of a heparin-coated circuit and aprotinin prime during open-heart surgery: potentiating effect on platelet preservation

[1]  A. Baue.  Cardiopulmonary Bypass for Cardiac Surgery: An Inflammatory Event: Can It Be Modulated? , 2000 .

[2]  N. Hayashida,et al.  Effects of minimal-dose aprotinin on coronary artery bypass grafting. , 1997, Journal of Thoracic and Cardiovascular Surgery.

[3]  S. Santoro,et al.  Evaluation of a New Point-of-care Test that Measures PAF-mediated Acceleration of Coagulation in Cardiac Surgical Patients , 1996, Anesthesiology.

[4]  S. Bannan,et al.  Thrombin generation with heparin-bonded cardiopulmonary bypass circuits. , 1996, Journal of Thoracic and Cardiovascular Surgery.

[5]  R. Colman,et al.  Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. , 1996, Circulation.

[6]  C. Baufreton,et al.  Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. , 1996, The Annals of thoracic surgery.

[7]  S. Ennis,et al.  Special Notice to Contributors , 1996 .

[8]  M. Pfisterer,et al.  Aprotinin in Aortocoronary Bypass Surgery: Increased Risk of Vein-Graft Occlusion and Myocardial Infarction? Supportive Evidence from a Retrospective Study , 1996, Thrombosis and Haemostasis.

[9]  W. van Oeveren,et al.  Retransfusion of thoracic wound blood during heart surgery obscures biocompatibility of the extracorporeal circuit. , 1996, The Journal of thoracic and cardiovascular surgery.

[10]  R. Colman,et al.  Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. , 1996, The Journal of thoracic and cardiovascular surgery.

[11]  A. Trowbridge,et al.  Recombinant aprotinin in coronary artery bypass graft operations. , 1995, The Journal of thoracic and cardiovascular surgery.

[12]  P. Bezemer,et al.  Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. , 1995, The Journal of thoracic and cardiovascular surgery.

[13]  D. Roberts,et al.  Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. , 1995, The Annals of thoracic surgery.

[14]  E. Spitznagel,et al.  Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[15]  E. Fosse,et al.  Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.

[16]  M. Pasic,et al.  Risk and benefit of low systemic heparinization during open heart operations. , 1994, The Annals of thoracic surgery.

[17]  B. Nilsson,et al.  Complement activation during cardiopulmonary bypass: effects of immobilized heparin. , 1994, The Annals of thoracic surgery.

[18]  W. van Oeveren,et al.  Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. , 1994, The Journal of thoracic and cardiovascular surgery.

[19]  T. Misaki,et al.  Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[20]  R. Mohr,et al.  Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study. , 1993, The Annals of thoracic surgery.

[21]  A. Lusky,et al.  Aprotinin Prevents Cardiopulmonary Bypass‐Induced Platelet Dysfunction: A Scanning Electron Microscope Study , 1992, Circulation.

[22]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[23]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[24]  G. Fuhrer,et al.  Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[25]  W. van Oeveren,et al.  Heparin-coating of extracorporea circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass , 1991 .

[26]  J. George,et al.  The clinical importance of acquired abnormalities of platelet function. , 1991, The New England journal of medicine.

[27]  J. E. Doran,et al.  Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[28]  O. Larm,et al.  Thrombin inactivation on surfaces with covalently bonded heparin. , 1986, Thrombosis research.

[29]  L. Harker.  Bleeding after cardiopulmonary bypass. , 1986, The New England journal of medicine.

[30]  A. Schwartz,et al.  Monitoring heparin anticoagulation and its neutralization. , 1981, The Annals of thoracic surgery.

[31]  R. Ponlot,et al.  Hæmostasis Disorders in Open Heart Surgery with Extracorporeal Circulation: Importance of the Platelet Function and the Heparin Neutralization , 1977, Vox sanguinis.

[32]  R. Ponlot,et al.  Haemostasis Disorders in Open Heart Surgery with Extracorporeal Circulation , 1977 .

[33]  F. Bachmann,et al.  The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. , 1975, The Journal of thoracic and cardiovascular surgery.